Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Palkovits, S; Seidel, G; Pertl, L; Malle, EM; Hausberger, S; Makk, J; Singer, C; Osterholt, J; Herzog, SA; Haas, A; Weger, M.
MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Retina. 2017; 37(12):2262-2268
Doi: 10.1097/IAE.0000000000001480
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Palkovits Stefan
- Co-Autor*innen der Med Uni Graz
- Haas Anton
- Herzog Sereina Annik
- Makk Johanna
- Malle Eva Maria Birgit
- Pinter-Hausberger Silke
- Posch-Pertl Laura
- Seidel Gerald
- Singer Christoph
- Weger Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To evaluate the effect of intravitreal bevacizumab on the macular choroidal volume and the subfoveal choroidal thickness in treatment naïve eyes with exudative age-related macular degeneration. The macular choroidal volume and the subfoveal choroidal thickness were measured using enhanced depth imaging optical coherence tomography. After a screening examination, each patient received 3 monthly intravitreal injections of 1.25 mg bevacizumab. One month after the third injection was a final assessment. Forty-seven patients with a mean age of 80 ± 6.4 years were included. The macular choroidal volume decreased significantly from median 4.1 mm (interquartile range 3.4-5.9) to median 3.9 mm (interquartile range 3.1-5.6) between the baseline and final examination (difference -0.46 mm, 95% confidence interval: -0.57 to 0.35, P < 0.001). Similarly, subfoveal choroidal thickness had decreased from 157.0 μm (interquartile range 116.0-244.5) at baseline to 139.0 μm (interquartile range 102.5-212.0) at the final examination (P < 0.001). Both parameters macular choroidal volume at baseline and subfoveal choroidal thickness at baseline were not associated with the response to treatment. The macular choroidal volume and the subfoveal choroidal thickness decreased significantly after 3 monthly bevacizumab injections for exudative age-related macular degeneration.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Angiogenesis Inhibitors - administration & dosage
- Bevacizumab - administration & dosage
- Choroid - pathology
- Dose-Response Relationship, Drug -
- Drug Administration Schedule -
- Fluorescein Angiography - methods
- Follow-Up Studies -
- Fundus Oculi -
- Humans -
- Intravitreal Injections -
- Macula Lutea - pathology
- Middle Aged -
- Organ Size -
- Prospective Studies -
- Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
- Time Factors -
- Tomography, Optical Coherence - methods
- Treatment Outcome -
- Visual Acuity -
- Wet Macular Degeneration - diagnosis
- Wet Macular Degeneration - drug therapy
- Find related publications in this database (Keywords)
- age-related macular degeneration
- bevacizumab
- choroidal thickness
- choroidal volume